We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+21.5%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.75B
AUM Growth
+$332M
Cap. Flow
-$28.9M
Cap. Flow %
-0.5%
Top 10 Hldgs %
51.71%
Holding
444
New
223
Increased
65
Reduced
45
Closed
77

Top Buys

Rank Stock Value
1
BNTX icon
BioNTech
BNTX
+$54.6M
2
KYTX icon
Kyverna Therapeutics
KYTX
+$40.8M
3
SGRY icon
Surgery Partners
SGRY
+$33.8M
4
LRMR icon
Larimar Therapeutics
LRMR
+$33.4M
5
ALHC icon
Alignment Healthcare
ALHC
+$30.6M

Top Sells

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$62.6M
2
SWTX
SpringWorks Therapeutics
SWTX
+$60.2M
3
BAX icon
Baxter International
BAX
+$55M
4
VKTX icon
Viking Therapeutics
VKTX
+$36.3M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$28.1M

Sector Composition

Rank Sector Weight
1 Healthcare 88.87%
2 Industrials 0.71%
3 Technology 0.31%
4 Consumer Discretionary 0.26%
5 Financials 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VSTM icon
51
Verastem
VSTM
$542M
$18.2M 0.32%
1,538,461
– –
QDEL icon
52
QuidelOrtho
QDEL
$1.19B
$16.7M 0.29%
348,000
– –
GH icon
53
Guardant Health
GH
$19.4B
$16.3M 0.28%
791,735
– –
FATE icon
54
Fate Therapeutics
FATE
$267M
$16.1M 0.28%
+2,190,408
New +$13.6M
NAMS icon
55
NewAmsterdam Pharma
NAMS
$3.33B
$15.8M 0.27%
+667,000
New +$13.5M
LNTH icon
56
Lantheus
LNTH
$6.65B
$14.9M 0.26%
+240,187
New +$14.1M
ENGN icon
57
enGene Therapeutics
ENGN
$117M
$13.6M 0.24%
+800,000
New +$9.79M
TNGX icon
58
Tango Therapeutics
TNGX
$4.25B
$12.2M 0.21%
1,540,000
– –
EYPT icon
59
EyePoint Inc
EYPT
$996M
$12M 0.21%
+579,594
New +$14.3M
COGT icon
60
Cogent Biosciences
COGT
$6.71B
$10.3M 0.18%
1,534,345
+445,000
+41% +$2.75M
ITOS
61
DELISTED
iTeos Therapeutics
ITOS
$9.86M 0.17%
723,000
– –
REPL icon
62
Replimune Group
REPL
$509M
$6.56M 0.11%
802,984
-1,008,726
-56% -$8.27M
ALEC icon
63
Alector
ALEC
$168M
$6.46M 0.11%
1,072,845
+5,035
+0.5% +$32.9K
PRME icon
64
Prime Medicine
PRME
$547M
$6.2M 0.11%
885,314
– –
GUTS icon
65
Fractyl Health
GUTS
$127M
$6.17M 0.11%
+834,254
New +$7.02M
WGS icon
66
GeneDx Holdings
WGS
$1.91B
$5.87M 0.1%
643,110
– –
TOI icon
67
The Oncology Institute
TOI
$487M
$5.31M 0.09%
3,360,052
– –
ANNX icon
68
Annexon
ANNX
$826M
$4.19M 0.07%
583,913
– –
CALC icon
69
CalciMedica
CALC
$11.4M
$4.16M 0.07%
+1,000,000
New +$4.57M
VIGL
70
DELISTED
Vigil Neuroscience
VIGL
$3.34M 0.06%
980,311
-193,212
-16% -$603K
PHGE icon
71
BiomX
PHGE
$1.93M
$2.75M 0.05%
+32,158
New +$1.69M
OMIC
72
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$2.56M 0.04%
166,162
– –
CMAX
73
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$2.55M 0.04%
529,108
+1
+0% +$8
CGON icon
74
CG Oncology
CGON
$6.38B
$2.09M 0.04%
+47,540
New +$1.94M
DXC icon
75
DXC Technology
DXC
$1.77B
$1.32M 0.02%
+62,245
New +$1.36M
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q1 2024 Portfolio in Review

As of Q1 2024, Deerfield Management held 444 positions worth $5.75B, up 6.1% from $5.42B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Deerfield Management's Q1 2024 filing shows 223 new, 65 increased, 45 reduced and 77 closed positions. Its largest new stake was BioNTech: 569,574 shares worth $52.5M. The largest sale was RayzeBio, Inc. Common Stock, an estimated $62.6M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 78% a quarter earlier, followed by Industrials and Technology.

  • Deerfield Management's largest Q1 2024 buy was BioNTech: 569,574 shares worth $52.5M.
  • Deerfield Management added most to Surgery Partners in Q1 2024, an estimated $33.8M increase.
  • Deerfield Management's biggest Q1 2024 reduction was SpringWorks Therapeutics, cutting an estimated $60.2M.
  • Deerfield Management fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $62.6M.
  • Deerfield Management's ten largest holdings make up 52% of its $5.75B portfolio in Q1 2024.
  • Deerfield Management opened 223 new positions and closed 77 in Q1 2024.
  • Deerfield Management's portfolio value rose 6.1% quarter-over-quarter to $5.75B.

Based on Deerfield Management's 13F filing for Q1 2024, filed 15 May 2024.